

AMENDMENTS TO THE SPECIFICATION

Under the heading of Example 1 on page 13, please replace the second full paragraph with the following rewritten paragraph:

To this patient, AHCC was continuously administered at a dosage of 3.0 g/day. One month after the start of the administration, the patient became able to eat 30% gruel or 50% gruel. The level of serum SCC tumor marker was 23 ~~ng/mL~~pg/mL before the administration (normal level: 2.0 ~~ng/mL~~pg/mL), but improved to 1.3 ~~ng/mL~~pg/mL one month after. By further continuing the administration, he became able to eat 100% gruel three months after the administration commencement, when the tumor was confirmed to have completely disappeared by fluoroscopic and CT examinations of esophagus.

On page 15, please replace Table 1 with the following rewritten Table 1:

Table 1

	Human Patient	Symptoms	NK Activity	Serum IL-12 Level	Treatment evaluation	CD4/CD8 ratio
Example 1	72-year-old; male	Esophagus cancer; surgery impossible; radiotherapy unresponsive; end-stage cancer	68%	78 ng/mL <u>pg/mL</u>	CR; complete regression	0.75
Example 2	36-year-old; male	right testis tumor; infant's head size metastasis to retroperitoneal lymph node; end-stage cancer	13%	120 ng/mL <u>pg/mL</u>	CR complete regression	0.52

On page 17, please replace Table 2 with the following rewritten Table 2:

Table 2

	Human Patient	Symptoms	NK activity	Serum IL-12 level	Treatment evaluation	CD4/CD8 ratio
Example 3	72-year-old; male	Stomach cancer; progressed stage	24%	240 ng/mL pg/mL	CR complete regression	0.34
Example 4	57-year-old; male	Caecum cancer; carcinomatous peritonitis; end-stage cancer	62%	230 ng/mL pg/mL	CR complete regression	0.42
Example 5	69-year-old; male	Stomach cancer; metastasis to liver; end-stage cancer	62%	103 ng/mL pg/mL	CR complete regression	0.62
Example 6	71-year-old; female	Hepatic cancer; metastasis to lung; end-stage cancer	68%	78 ng/mL pg/mL	PR; metastasis disappear	

On page 18, please replace Table 3 with the following rewritten Table 3:

Table 3

	Human patient	Symptoms	NK Activity	Serum IL-12 level	Treatment evaluation	CD4/CD8 ratio
Example 7	67-year-old; male	left lung cancer; metastasis to right lung; metastasis to liver; end-stage cancer	32%	240 ng/mL <u>pg/mL</u>	PR; right lung metastasis disappear	0.43
Example 8	73-year-old; female	right lung cancer; metastasis to left lung; metastasis to liver; end-stage cancer	29%	340 ng/mL <u>pg/mL</u>	PR; lung metastasis disappear	0.43

On page 20, please replace Table 4 with the following rewritten Table 4:

Table 4

	Human Patient	Symptoms	NK activity	Serum IL-12 level	Treatment evaluation	CD4/CD8 ratio
Comparative example 1	23-year-old; male	Stomach cancer; carcinomatous peritonitis end-stage cancer	32%	240 ng/mL pg/mL	CR complete regression	0.72
Comparative example 2	72-year-old; male	Hepatic cancer; carcinomatous peritonitis end-stage cancer	40%	260 ng/mL pg/mL	PR $\frac{3}{4}$ Of Hepatic Cancer disappearance	0.32